For Eisai, success against Alzheimer’s has been a long time coming

It took 25 years after the company's introduction of Aricept to develop another Alzheimer's treatment that proved effective in human trials. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     ‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer's has been a long time coming By Adam Feuerstein, Jason Mast, and Damian garde Chantal Heijnen for STAT The success of the Alzheimer's treatment lecanemab gives Eisai a chance to make good on years of fruitless labor and to resolve what one executive described as “unfinished business.”  “We remember all those failed promises, and think about all those families we lost,” said Ivan Cheung (above), chairman of Eisai’s U.S. operations. “We always told these patient communities that we’re working on the next-generation drug. Of course, it took us much longer.” Read More Sponsored insight by BOEHRINGER INGELHEIM AND LILLY Studies show that patients with cardio-renal-metabolic conditions benefit from holistic care   Cardio-renal-metabolic (C-R-M) conditions are a group of interconnected disorders — such as cardiovascular disease, chronic kidney disease and type 2 diabetes — accounting for up to 20 million deaths annually in the U.S. and collectively rank as a leading cause of death worldwide. While medical guidelines are calling on healthcare professionals to collaborate when treating patients with C-R-M conditions to improve health outcomes, adoption in clinical practice still lags. According to medical experts, there are challenges specialists can face in changing engrained behavior. Here’s what the healthcare community can do to overcome those challenges. More great reads from STAT this week ‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process By Ed Silverman After decades of setbacks, scientists make strides toward the holy grail of male birth control By Eleanor Cummins Meet the 2022 STAT Wunderkinds By STAT staff The FDA has banned certain vapes and medicines. We still bought these 13 products in its backyard By Nicholas Florko Nectar bats are ‘wonderful, majestic’ and sugar-obsessed. This researcher wants to know how they stay healthy By Justin Chen 5 looming questions about the exodus of young life scientists from academia By Jonathan Wosen Opinion: Better access to amyloid-PET scans won’t reduce racial inequities in Alzheimer’s disease By Poul Høilund-Carlsen, Abass Alavi and Jorge R. Barrio Boom and bust: Whose biotech VC assets have grown and shrunk the most? By Allison DeAngelis and Kate Sheridan Saturday, November 19, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser